Insight Molecular Diagnostics (IMDX) Amortization of Deferred Charges (2017 - 2022)

Insight Molecular Diagnostics (IMDX) has 6 years of Amortization of Deferred Charges data on file, last reported at $1000.0 in Q3 2022.

• Quarterly Amortization of Deferred Charges fell 92.31% year-over-year to $1000.0 in Q3 2022, while the trailing twelve-month figure through Dec 2022 was $12000.0 (down 78.57% YoY) and the FY2022 annual result came in at $12000.0, down 78.57% from the prior year.
• Amortization of Deferred Charges slipped to $1000.0 in Q3 2022 per IMDX's latest filing, from $4000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $35000.0 in Q1 2020, with the low at $1000.0 in Q3 2022.
• Average Amortization of Deferred Charges over 5 years is $16105.3, with a median of $15000.0 recorded in 2018.
• Year-over-year, Amortization of Deferred Charges soared 633.33% in 2018 and plunged 92.31% in 2022.
• Insight Molecular Diagnostics' Amortization of Deferred Charges stood at $15000.0 in 2018, then jumped by 93.33% to $29000.0 in 2019, then fell by 24.14% to $22000.0 in 2020, then tumbled by 54.55% to $10000.0 in 2021, then slumped by 90.0% to $1000.0 in 2022.
• Business Quant data shows IMDX's Amortization of Deferred Charges at $1000.0 in Q3 2022, $4000.0 in Q2 2022, and $7000.0 in Q1 2022.